Effect of dapagliflozin on proteinuria and the slope of the estimated glomerular filtration rate in patients with immunoglobulin A nephropathy: A multicenter prospective study.

ABSTRACT: ObjectiveThe sodium-glucose cotransporter-2 inhibitor dapagliflozin reduces proteinuria and slows the decline in estimated glomerular filtration rate in patients with chronic kidney disease. Dapagliflozin is reported to be effective in patients with immunoglobulin A nephropathy; however, there have been only a few real-world clinical trials involving patients with immunoglobulin A nephropathy. Therefore, we aimed to evaluate the effect of dapagliflozin in Japanese patients with immunoglobulin A nephropathy.MethodWe performed a multicenter, nonblinded, single-arm, prospective observational study involving 44 patients with immunoglobulin A nephropathy. Patients who had completed corticosteroid treatment and were currently undergoing renin-angiotensin system inhibitor therapy were primarily e

SUBMITTER: Koshida T 

PROVIDER: S-EPMC12446846 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature